The data report should be viewed as a "positive validation" for the company's RNA repair platform for two reasons, the analyst noted. First, it validates clinical safety and tolerability, and second, it gives the company the opportunity to now evaluate its platform in a bigger and more severe CF population group. However, the company has yet to confirm any future developments but it is evaluation collaborations as a combo therapy or as a monotherapy.
Yet despite the encouraging data, the analyst still sees a 30 percent probability of success which does mark an increase from a prior estimate of just 20 percent. Also, the company's peak penetration now stands at 33 percent which is lower from a prior 45 percent estimate to reflect the "increasingly competitive CF landscape."
At time of publication, shares of ProQR were down 10.76 percent at $5.76.Related Links: 22 Stocks Moving In Tuesday's Pre-Market Session The Market In 5 Minutes: Tech Stocks Look To Bounce Back
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.